SCHEMBL2425450

SCHEMBL2425450

CCOC(=O)C(Cc1cccc(OC)c1)C(C)=O

nearest known ligand 0.56

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.56
MAPK1 P28482 3/20 0.56
L3MBTL1 Q9Y468 3/20 0.56
TSHR P16473 2/20 0.56
TDP1 Q9NUW8 2/20 0.56
TAAR1 Q96RJ0 2/20 0.51
MMP8 P22894 1/20 0.48
KDM4E B2RXH2 2/20 0.47
MAPT P10636 1/20 0.47
TP53 P04637 1/20 0.46
MTNR1A P48039 1/20 0.46
MTNR1B P49286 1/20 0.46
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
MDM2 Q00987 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2672357 0.93 ALDH1A1 (0.60) ALDH1A1MAPK1L3MBTL1TSHRTDP1
SCHEMBL15261978 0.89 TAAR1 (0.54) ALDH1A1TAAR1MTNR1AMTNR1BMEN1
SCHEMBL4725563 0.88 TAAR1 (0.60) ALDH1A1TAAR1MTNR1AMTNR1BMEN1
SCHEMBL17281 0.84 TAAR1 (0.60) ALDH1A1MAPK1L3MBTL1TSHRTDP1
SCHEMBL31506228 0.84 TAAR1 (0.60) ALDH1A1MAPK1L3MBTL1TSHRTDP1
SCHEMBL17280 0.84 TAAR1 (0.60) ALDH1A1MAPK1L3MBTL1TSHRTDP1
SCHEMBL3573062 0.84 L3MBTL1 (0.52) ALDH1A1MAPK1L3MBTL1TSHRTDP1
SCHEMBL7642003 0.84 MAPK1 (0.62) ALDH1A1MAPK1L3MBTL1TSHRTDP1
SCHEMBL4564004 0.84 MAPK1 (0.52) ALDH1A1MAPK1L3MBTL1TSHRTDP1
SCHEMBL2429158 0.84 ALDH1A1 (0.59) ALDH1A1MAPK1L3MBTL1TSHRTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11851435-B2 PTGR2 inhibitors and their use NATIONAL HEALTH RESEARCH INSTITUTES (TW) 2023-12-26 US disclosed
US-20230279008-A1 PTGR2 INHIBITORS AND THEIR USE NATIONAL TAIWAN UNIVERSITY (TW) 2023-09-07 US disclosed
WO-2011114148-A1 4H- [1, 2, 4] TRIAZOLO [5, 1 -B] PYRIMIDIN-7 -ONE DERIVATIVES AS CCR2B RECEPTOR ANTAGONISTS ASTRAZENECA AB (SE) 2011-09-22 WO disclosed
WO-2007144625-A1 2-OXO-2H-CHROMENE COMPOUNDS ARGENTA DISCOVERY LIMITED (GB) 2007-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11851435-B2 PTGR2 inhibitors and their use PTGFR, PTGIR, PTGDR2 ALDH1A1 1177/4885MAPK1 1084/4885L3MBTL1 4693/4885
US-20230279008-A1 PTGR2 INHIBITORS AND THEIR USE PTGFR, PTGIR, PTGDR2 ALDH1A1 1177/4885MAPK1 1084/4885L3MBTL1 4693/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.